By the Top Tier Newswire AI Desk · July 17, 2026 at 12:03 AM ET · reviewed against 29 wire stories
ATAIBECKLEY INC (ATAI) is up +33.40% in the latest session. Our newswire has captured 29 stories on ATAI across 18 sources in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Why ATAI stock is up today
ATAI stock rose 33.40% to $7.15 in a single session driven by the announcement of an acquisition by Eli Lilly. The deal, which includes a cash payment of $6.75 per share and a contingent value right (CVR), has sparked strong investor interest. This acquisition marks a significant development for the clinical-stage psychedelics developer.
What Happened
The surge in ATAI shares came after Eli Lilly announced a definitive agreement to acquire AtaiBeckley for an initial $2.8 billion, with the potential to reach up to $3.8 billion through milestone payments. The deal is expected to bolster Eli Lilly's neuroscience pipeline and aligns with the company's ongoing strategy to expand in the mental health sector. The acquisition price of $6.75 per share represents a 26% premium over the stock's previous closing price. The Fly reported that Canaccord increased its coverage of ATAI earlier in July, but recent downgrades from Needham and Canaccord have tempered expectations. Despite these mixed signals, the acquisition news has overshadowed recent analyst activity.
What The Data Shows
ATAI's stock has surged 46.9% over the past eight sessions, rising from $4.89 to $7.19. The stock's 52-week range is $2.58 to $6.75, meaning today's close is above its previous high. The company has a market cap of $1.8 billion and remains unprofitable with an EPS of -2.44 for the trailing twelve months. Revenue has increased by 87.2% in the same period. Insider selling has been active recently, with three separate transactions totaling $938K in the last 90 days. The stock's beta of 1.57 indicates higher volatility than the broader market.
What To Watch
The acquisition by Eli Lilly is expected to close in the coming months, but no specific date has been provided. Investors should monitor the progress of the deal and any regulatory developments. Coverage from analysts remains mixed, so further ratings changes could influence the stock's trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
ATAI · Jul 17 session (5-min) · 0.00% vs prior close · updated 8:59 PM ETAI sentiment, last 36h · averaged over 29 stories · 67/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
13d agoStocktwits NewsBULLISH 68Earnings
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today?
Apple, AtaiBeckley and UnitedHealth Group jumped to yearly highs as positive company catalysts, Wall Street upgrades, and strong earnings pushed shares higher.
13d agoYahoo TopBULLISH 67Analyst
Here Is Why AtaiBeckley (ATAI) Is One Of The 10 Best Stocks Under $10 That Could Triple
AtaiBeckley N.V. (NASDAQ:ATAI) is one of the 10 best stocks under $10 that could triple. On June 25, AtaiBeckley N.V. (NASDAQ:ATAI) shared that the company will be included in the Russell indices following their latest reconstitution. The stock will become a part of the small-cap focused Russell 2000 Index, as well as the broader Russell […]
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree. Eli Lilly said it will pay $6.75 a share in cash for AtaiBeckley, a 26% premium to Wednesday's closing price of $5.36 for the New York clinical-stage biopharmaceutical company.
13d agoThe Motley FoolBULLISH 68M&A
Why AtaiBeckley Stock Soared Today
The psychedelic drugmaker is being acquired.
13d agoThe Motley FoolBULLISH 82M&A
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
13d agoYahoo FinanceBULLISH 63Analyst
Is AtaiBeckley Inc. (ATAI) Stock a Psychedelic Medicine Opportunity Ahead of Phase 2 Results?
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best psychedelic stocks on our list. TheFly reported on July 7 that Canaccord increased its price target on ATAI to $17 from $15 while maintaining a Buy rating on the shares. The firm […]
13d agoSeeking AlphaBULLISH 56M&A
AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline
AtaiBeckley is being acquired by Eli Lilly at $6.75/share plus a $2.50 CVR—see the deal terms, milestone risks, and pipeline outlook. Click to read more.
13d agoPR NewswireBEARISH 34General
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI)
NEW YORK, July 16, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →